ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=P  !"#$%&'(=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri General;6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_)3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)\(#,##0_);[RED]\(#,##0\) #,##0 #,##0.00!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\)                + ) , *   (  $ ( (8  $       (8    $  $ ` TableBTable-1Table-2*Table-3İTable-4~Table-5Table-6Table-7Table-8Table-9JTable-10LTable-11rTable-12Table-13|Table-14hTable-15p%Table-16l(Table-17h2Table-185Table-198Table-20j<Table-21$@Table-22&CTable-23@GTable-24NKTable-25heTable-26>lTable-27rTable-28wTable-29P{Table-30BTable-31Table-32څTable-33Table-34ڍTable-35ґTable-36Table-37&Table-38Table-39TP)((      !"#$%&'(3  @@   * Fiscal 2011 Fiscal 2010HighLow%First Quarter (November 1-January 31)%Second Quarter (February 1- April 30)Third Quarter (May 1 - July 31)&Fourth Quarter (August 1 - October 31)Nameand Principal Position Fiscal YearSalaryBonusStock Award(s) (1)Option Award(s) (1)AllOther CompensationTotalThomas A. Moore,2011$-CEO and Chairman2010Dr. John Rothman,-$Executive VP of Science & OperationsMark J. RosenblumChief Financial Officer OptionAwards StockAwardsNameCNumberof Securities Underlying Unexercised Options(#) ExercisableENumber of Securities Underlying Unexercised Options (#) Unexercisable_Equity Incentive PlanAwards: Number of Securities Underlying Unexercised Unearned Options (#)Option Exercise Price($)Option Expiration Date;Number of Shares Or Units of Stock That Have Not Vested (#)AMarket Value of Shares Or Units of Stock That Have Not Vested ($)gEquity Incentive Plan Awards: Number of Unearned Shares, Units Or Other Rights That Have Not Vested (#)wEquity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units Or Other Rights That Have Not Vested ($)Thomas A. Moore 7/21/19$ 12/15/1610/14/20Dr. John Rothman3/1/153/29/162/15/171/05/20Fees Earned orPaid inCash ($)Stock Awards ($)(1)Option Awards ($)(1)Allother Compensation ($) Total ($) Roni A. AppelDr. James PattonDr. Thomas McKearnRichard Berman$NameandAddress ofBeneficialOwner8Numberof SharesofourCommon Stock BeneficiallyOwned&Percentage ofClass BeneficiallyOwned4.99%2.6%*%1.3%*1.9%BAll Current Directors and Executive Officers as a Group (7 people)12.4%FiscalYear 2011FiscalYear 2010$Audit Fees-McGladrey and Pullen, LLP,Audit Related Fees-McGladrey and Pullen, LLP Tax Fees-RSM McGladrey, Inc. (1)Securities Purchase Agreement between the registrant and the purchasers in the private placement (the  SPA ), dated as of October 17, 2007, and Disclosure Schedules thereto.Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Securities Purchase Agreement dated February 2, 2006 between the registrant and Cornell Capital Partners, LP.Incorporated by reference to Exhibit 10.01 to Report on Form 8-K filed with the SEC on February 8, 2006.Registration Rights Agreement between the registrant and the parties to the SPA, dated as of October 17, 2007.Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Placement Agency Agreement between the registrant and Carter Securities, LLC, dated as of October 17, 2007.Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Engagement Letter between the registrant and Carter Securities, LLC, dated August 15, 2007.Incorporated by reference to Exhibit 10.3(a) to Current Report on Form 8-K filed with the SEC on October 23, 2007.Agreement between the registrant and YA Global Investments, L.P. f/k/a Cornell Capital Partners, L.P., dated August 23, 2007.Incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed with the SEC on October 23, 2007.=Memorandum of Agreement between the registrant and CAMHZN Master LDC and CAMOFI Master LDC, purchasers of the Units consisting of common stock, $0.20 warrants, and $0.001 warrants, dated October 17, 2007.Incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Advisory Agreement between the registrant and Centrecourt Asset Management LLC, dated August 1, 2007.Incorporated by reference to Exhibit 10.6 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Share Exchange and Reorganization Agreement, dated as of August 25, 2004, by and among the registrant, Advaxis and the shareholders of Advaxis.Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 18, 2004.Security Agreement dated February 2, 2006 between the registrant and Cornell Capital Partners, L.P.Incorporated by reference to Exhibit 10.06 to Current Report on Form 8-K filed with the SEC on February 8, 2006.Investor Registration Rights Agreement dated February 2, 2006 between the registrant and Cornell Capital Partners, LP.Incorporated by reference to Exhibit 10.05 to Current Report on Form 8-K filed with the SEC on February 8, 2006.2004 Stock Option Plan of the registrant.Incorporated by reference to Exhibit 4.1 to Report on Form S-8 filed with the SEC on December 1, 2005.2005 Stock Option Plan of the registrant.Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on May 15, 2006.License Agreement, between University of Pennsylvania and the registrant dated as of June 17, 2002, as Amended and Restated on February 13, 2007.Incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-KSB filed with the SEC on February 13, 2007.Sponsored Research Agreement dated November 1, 2006 by and between University of Pennsylvania (Dr. Paterson Principal Investigator) and the registrant.Incorporated by reference to Exhibit 10.44 to Annual Report on 10-KSB filed with the SEC on February 13, 2007.'Non-Exclusive License and Bailment, dated as of March 17, 2004, between The Regents of the University of California and Advaxis, Inc. Incorporated by reference to Exhibit 10.8 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Consultancy Agreement, dated as of January 19, 2005, by and between LVEP Management, LLC. and the registrant. Incorporated by reference to Exhibit 10.9 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Amendment to Consultancy Agreement, dated as of April 4, 2005, between LVEP Management LLC and the registrant. Incorporated by reference to Exhibit 10.27 to Annual Report on Form 10-KSB filed with the SEC on January 25, 2006.Second Amendment dated October 31, 2005 to Consultancy Agreement between LVEP Management LLC and the registrant. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on November 9, 2005.Third Amendment dated December 15, 2006 to Consultancy Agreement between LVEP Management LLC and the registrant. Incorporated by reference to Exhibit 9.01 to Current Report on Form 8-K filed with the SEC on December 15, 2006. Consultancy Agreement, dated as of January 22, 2005, by and between Dr. Yvonne Paterson and Advaxis, Inc. Incorporated by reference to Exhibit 10.12 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504). Consultancy Agreement, dated as of March 15, 2003, by and between Dr. Joy A. Cavagnaro and Advaxis, Inc. Incorporated by reference to Exhibit 10.13 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Consulting Agreement, dated as of July 2, 2004, by and between Sentinel Consulting Corporation and Advaxis, Inc. Incorporated by reference to Exhibit 10.15 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Agreement, dated July 7, 2003, by and between Cobra Biomanufacturing PLC and Advaxis, Inc. Incorporated by reference to Exhibit 10.16 to Pre-Effective Amendment No. 4 filed on June 9, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Securities Purchase Agreement, dated as of January 12, 2005, by and between the registrant and Harvest Advaxis LLC. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed wit< h the SEC on January 18, 2005.Registration Rights Agreement, dated as of January 12, 2005, by and between the registrant and Harvest Advaxis LLC. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on January 18, 2005.Letter Agreement, dated as of January 12, 2005 by and between the registrant and Robert T. Harvey. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on January 18, 2005. Consultancy Agreement, dated as of January 15, 2005, by and between Dr. David Filer and the registrant. Incorporated by reference to Exhibit 10.20 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Consulting Agreement, dated as of January 15, 2005, by and between Pharm-Olam International Ltd. and the registrant. Incorporated by reference to Exhibit 10.21 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Letter Agreement, dated February 10, 2005, by and between Richard Berman and the registrant. Incorporated by reference to Exhibit 10.23 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Employment Agreement, dated February 8, 2005, by and between Vafa Shahabi and the registrant. Incorporated by reference to Exhibit 10.24 to Pre-Effective Amendment No. 2 filed on April 28, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Employment Agreement, dated March 1, 2005, by and between John Rothman and the registrant.Incorporated by reference to Exhibit 10.25 to Pre-Effective Amendment No. 2 filed on April 8, 2005 to Registration Statement on Form SB-2/A (File No. 333-122504).Clinical Research Services Agreement, dated April 6, 2005, between Pharm-Olam International Ltd. and the registrant.Incorporated by reference to Exhibit 10.26 to Pre-Effective Amendment No. 4 filed on June 9, 2005 to Registration Statement on Form SB-2 (File No. 333-122504). Royalty Agreement, dated as of May 11, 2003, by and between Cobra Bio-Manufacturing PLC and the registrant.Incorporated by reference to Exhibit 10.28 to Pre-Effective Amendment No. 4 filed on June 9, 2005 to Registration Statement on Form SB-2 (File No. 333-122504).Letter Agreement between the registrant and Investors Relations Group Inc., dated September 27, 2005.Incorporated by reference to Exhibit 10.31 to Post-Effective Amendment filed on January 5, 2006 to Registration Statement on Form SB-2 (File No. 333-122504).Consultancy Agreement between the registrant and Freemind Group LLC, dated October 17, 2005.Incorporated by reference to Exhibit 10.32 to Post-Effective Amendment filed on January 5, 2006 to Registration Statement on Form SB-2 (File No. 333-122504).Employment Agreement dated August 21, 2007 between the registrant and Thomas Moore.Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on August 27, 2007.Employment Agreement dated February 9, 2006 between the registrant and Fred Cobb.Incorporated by reference to Exhibit 10.35 to the Registration Statement on Form SB-2 (File No. 333-132298) filed with the SEC on March 9, 2006.Termination of Employment Agreement between J. Todd Derbin and the registrant dated October 31, 2005.Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 9, 2005.Consulting Agreement dated June 1, 2006 between the registrant and Biologics Consulting Group Inc.Incorporated by reference to Exhibit 10.40 to Annual Report on Form 10-KSB field with the SEC on February 13, 2007.Consulting Agreement dated June 1, 2006 between the registrant and Biologics Consulting Group Inc., as amended on June 1, 2007.Incorporated by reference to Exhibit 10.42(i) to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Master Contract Service Agreement between the registrant and MediVector, Inc. dated May 20, 2007. Incorporated by reference to Exhibit 10.44 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Form of note issued in the August 2007 financing.Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on August 27, 2007.Letter of Agreement, dated November 21, 2007, between Crystal Research Associates, LLC and the registrant. Incorporated by reference to Exhibit 10.45 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.3Service Proposal O781, dated May 14, 2007, to the StrategicCollaboration and Long Term Vaccine Supply Agreement, dated October 31, 2005, between the registrant and Cobra Biomanufacturing Plc. Incorporated by reference to Exhibit 10.46 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.4Service Proposal, dated September 20, 2007, to the StrategicCollaboration and Long Term Vaccine Supply Agreement, dated October 31, 2005, between the registrant and Cobra Biomanufacturing Plc. Incorporated by reference to Exhibit 10.47 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Consulting Agreement, dated May 1, 2007 between the registrant and Bridge Ventures, Inc. Incorporated by reference to Exhibit 10.48 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Consulting Agreement, dated August 1, 2007 between the registrant and Dr. David Filer. Incorporated by reference to Exhibit 10.49 to Annual Report on Form 10-KSB filed with the SEC on January 16, 2008.Employment Agreement dated February 29, 2008 between the registrant and Christine Chansky. Incorporated by reference to Exhibit 10.50 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Note Purchase Agreement, dated September 22, 2008 by and between Thomas A. Moore and the registrant. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on September 30, 2008.Lease Extension Agreement dated June 1, 2008 by and between New Jersey Economic Development Authority and the registrant. Incorporated by reference to Exhibit 10.55 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Technical/Quality Agreement dated May 6, 2008 by and between Vibalogics GmbH and the registrant. Incorporated by reference to Exhibit 10.57 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Master Service Agreement dated April 7, 2008 by and between Vibalogics GmbH and the registrant. Incorporated by reference to Exhibit 10.58 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Agreement, dated as of December 8, 2008, by and between The Sage Group and the registrant. Incorporated by reference to Exhibit 10.59 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Service Agreement dated January 1, 2009 by and between AlphaStaff, Inc. and the registrant. Incorporated by reference to Exhibit 10.60 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Promissory Note issued to Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, dated November 10, 2003.Incorporated by reference to Exhibit 10.53 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Promissory Note issued to Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, dated December 17,2003.Incorporated by reference to Exhibit 10.54 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Letter of Intent dated November 20, 2008 by and between Numoda Corporation and the registrant. Incorporated by reference to Exhibit 10.61 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Consulting Agreement dated December 1, 2008 by and between Conrad Mir and the registrant. Incorporated by reference to Exhibit 10.62 to Annual Report on Form 10-KSB filed with the SEC on January 29, 2009.Form of Note Purchase Agreement. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Senior Secured Convertible Note. Incorporated by refe< rence to Exhibit 4.2 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Senior Promissory Note as amended, between the registrant and Thomas Moore. Incorporated by reference to Exhibit 4.3 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Security Agreement. Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Form of Subordination Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on June 19, 2009.Series A Preferred Stock Purchase Agreement dated September 24, 2009 by and between Optimus Capital Partners, LLC and the registrant. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on September 25, 2009.Form of Note Purchase Agreement, entered into in connection with the junior bridge financing. Incorporated by reference to Exhibit 10.61 to Registration Statement on Form S-1 (File No. 333-162632) filed with the SEC on October 22, 2009.Form of Convertible Promissory Note, issued in the junior bridge financing.Incorporated by reference to Exhibit 4.13 to Registration Statement on Form S-1 (File No. 333-162632) filed with the SEC on October 22, 2009.Form of Amended and Restated Senior Promissory Note, between the registrant and Thomas Moore.Incorporated by reference to Exhibit 4.17 to Annual Report on Form 10-K filed with the SEC on February 19, 2010.Amendment to Senior Promissory Note.Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K/A filed with the SEC on February 11, 2010.Amended and Restated 2009 Stock Option Plan of the registrant.Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 30, 2010.Form of Stock Purchase Agreement dated May 10, 2010 between the registrant and Numoda Capital Innovations, LLC.Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on May 14, 2010. Second Amendment to the Amended and Restated Patent License Agreement between the registrant and the University of Pennsylvania dated as of May 10, 2010.Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 3, 2010.Series B Preferred Stock Purchase Agreement dated July 19, 2010 by and between Optimus Capital Partners, LLC and the registrant. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 20, 2010.Form of Amended and Restated Promissory Note between Optimus CG II Ltd. and the registrant. Incorporated by reference to Exhibit G to the Purchase Agreement included as Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 20, 2010.Form of Security Agreement between Optimus CG II Ltd. and the registrant. Incorporated by reference to Exhibit H to the Purchase Agreement included as Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 20, 2010.Separation Agreement and General Release dated January 6, 2010 between the Company and Fred Cobb.Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on September 14, 2010.Form of Note Purchase Agreement.Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 12, 2010.Page Advaxis, Inc.7Report of Independent Registered Public Accounting FirmF-10Balance Sheets as of October 31, 2011 and 2010F-2Statements of Operations for the years ended October 31, 2011 and 2010 and the cumulative period from March 1, 2002 (Inception) to October 31, 2011F-3qStatements of Stockholders Equity (Deficiency) for the Period from March 1, 2002 (Inception) to October 31, 2011F-4Statements of Cash Flows for the years ended October 31, 2011 and 2010 and the cumulative period from March 1, 2002 (Inception) to October 31, 2011F-5!Notes to the Financial StatementsF-7October31, 2011October31, 2010ASSETSCurrent Assets:CashOther Current AssetReceivableGrant ReceivablePrepaid expensesOther Current AssetsTotal Current AssetsDeferred expenses8Property and Equipment (net of accumulated depreciation)3Intangible Assets (net of accumulated amortization)Deferred Financing Cost Other Assets TOTAL ASSETS(LIABILITIES AND SHAREHOLDERS DEFICIENCYCurrent Liabilities:Accounts payableAccrued expensesBShort-term Convertible Notes and fair value of embedded derivative;Notes payable  current portion, including interest payableTotal Current Liabilities Deferred RentLong-term Convertible NotesCommon Stock WarrantTotal LiabilitiesShareholders Deficiency:Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at October 31, 2011 and 789 at October 31, 2010. Series A Preferred Stock; issued and outstanding 0 at October 31, 2011 and 0 at October 31, 2010Common Stock - $0.001 par value; authorized 500,000,000 shares, issued and outstanding 250,173,570 in 2011 and 198,100,817 in 2010Additional Paid-In CapitalPromissory Note Receivable0Deficit accumulated during the development stageTotal Shareholders Deficiency,TOTAL LIABILITIES & SHAREHOLDERS DEFICIENCYYearEnded October31,4Periodfrom March1,2002 (Inception)to October31,RevenueResearch & Development Expenses 4, 904,298!General & Administrative ExpensesTotal Operating expensesLoss from OperationsOther Income (expense):Interest expense Other Income(Gain) Loss on note retirementWrite-off of intangible assets]Net changes in fair value of common stock warrant liability and embedded derivative liability"Net Loss before income tax benefitIncome Tax BenefitNet Loss*Dividends attributable to preferred shares#Net Loss applicable to Common StockNet Loss per share, basicNet Loss per share, diluted4Weighted average number of shares outstanding, basic6Weighted average number of shares outstanding, dilutedPreferredStock CommonStockDeficit NumberofStock AccumulatedSharesof OutstandingAmountNumberofshares ofoutstandingSubscription ReceivableAdditionalPaid- inCapitalDuringthe DevelopmentStage!Shareholders Equity(Deficiency)Preferred stock issuedCommon Stock Issued.Options granted to consultants & professionalsERetroactive restatement to reflect re-capitalization on Nov. 12, 2004Balance at December 31, 2002+Note payable converted into preferred stock0Options granted to consultants and professionalsNet lossBalance at December 31, 2003!Stock dividend on preferred stockBalance at October 31, 2004;Common Stock issued to Placement Agent on re-capitalizationEffect of re-capitalization*Conversion of Note payable to Common StockCIssuance of Common Stock for cash, net of shares to Placement Agent'Issuance of common stock to consultantsFIssuance of common stock in connection with the registration statementIssuance costsYRestatement to reflect re- capitalization on Nov. 12, 2004 including cash paid of $44,940Balance at October 31, 2005*Options granted to employees and directors'Conversion of debenture to Common Stock3Issuance of Common Stock to employees and directorsBalance at October 31, 2006Common Stock issuedOffering Expenses<Warrants issued on conjunction with issuance of common stockBalance at October 31, 2007Common Stock Penalty SharesWarrants issued to consultantBalance at October 31, 2008-Common stock issued upon exercise of warrants#Warrants classified as a liability!Issuance of common Stock Warrants0Options granted to professionals and consultants3Issuance of common stock to employees and directors< Net Income/ (Loss)Balance at October 31, 2009Preferred Stock issued3Common stock issued upon conversion of Bridge NotesCommon stock issued to Numoda1Common stock issued to University of Pennsylvania.Common stock issued to employees and directors'Common stock issued to former employees!Issuance of common stock warrantsBalance at October 31, 2010Preferred Stock redeemedOptions granted to consultants-Common stock issued upon exchange of warrants5Common stock issued upon conversion of May 2011 Notes&Common stock issued to former employee"Common stock issued to consultants/Reclassification of warrant liability to equityRReclassification of Embedded Derivative Liability to Beneficial Conversion Feature$Interest on Optimus Notes ReceivableBalance at October 31, 2011 PeriodfromMarch12002 Yearended(Inception)to October31,OPERATING ACTIVITIESKAdjustments to reconcile net loss to net cash used in operating activities:CNon-cash charges to consultants and employees for options and stock(Amortization of deferred financing costs(Amortization of discount on Bridge LoansImpairment of intangible assetsNon-cash interest expenseB(Gain) Loss on change in value of warrants and embedded derivativeWarrant ExpenseValue of penalty shares issuedDepreciation expense#Amortization expense of intangiblesInterest Income(Gain) Losson note retirement+Change in operating assets and liabilities:'(Increase) decrease in prepaid expenses'(Increase) decrease in grant receivable+(Increase) decrease in other current assets(Increase) in other assets((Increase) decrease in deferred expensesIncrease in accounts payableIncrease in accrued expenses'(Decrease) increase in interest payableIncrease in deferred rent%Net cash used in operating activitiesINVESTING ACTIVITIES.Cash paid on acquisition of Great Expectations"Purchase of property and equipmentCost of intangible assets%Net cash used in Investing ActivitiesFINANCING ACTIVITIES+Proceeds from convertible secured debenture1(Increase) decrease in deferred offering expenses&Cash paid for deferred financing costsProceeds from notes payablePayment on notes payable+Net proceeds of issuance of Preferred Stock#Payment on cancellation of Warrants&Proceeds from the exercise of warrants(Net proceeds of issuance of Common Stock)Net cash provided by Financing ActivitiesNet increase (decrease) in cashCash at beginning of periodCash at end of periodCash paid for Interest March1,2002 October 31,&Equipment acquired under notes payable$$Common Stock issued to Founders?Notes payable and accrued interest converted to Preferred Stock!Stock dividend on Preferred Stock;Accounts payable from consultants settled with common stockMNotes payable and embedded derivative liabilities converted to Common Stock-Intangible assets acquired with notes payable,Intangible assets acquired with common stockbDebt discount in connection with recording the original value of the embedded derivative liabilityEAllocation of the original secured convertible debentures to warrants;Allocation of the warrants on Bridge Notes as debt discount;Note Receivable in connection with the exercise of warrants;Warrants issued in connection with issuance of Common Stock>Warrants issued in connection with issuance of Preferred StockAsofOctober31,Warrants Stock Options0Convertible Debt (using the if-converted method)5March1,2002 (dateof inception)to October31, 2011Net Loss as reported=Add: Stock based option expense included in recorded net lossQDeduct stock option compensation expense determined under fair value based methodAdjusted Net Loss YearEndedExpected volatility150.44%156.5% Expected Life 10.0 yearsDividend yieldRisk-free interest rate3.50%2.75%LicensePatentsTotal intangiblesAccumulated AmortizationIntangible AssetsYear ended October 31,20122013201420152016Salaries and other compensationSponsored Research Agreement$Clinical Research Organization (CRO) ConsultantsLegalOtherBShort-term Convertible Promissory Notes  Principal Value - Issued"Principal payments on Bridge Notes2Short-term Convertible Promissory Note ConversionsBridge Note Exchanges1Original Issue Discount, net of accreted interest+Fair Value of Attached Warrants at issuance.Fair Value of Embedded Derivatives at issuance@Accreted interest on embedded derivative and warrant liabilities*Convertible Notes- as of October 31, 20112Embedded Derivatives Liability at October 31, 2011NShort-Term Convertible Promissory Notes and fair value of embedded derivative Description PrincipalOriginal Issue DiscountWarrant LiabilityEmbedded Derivative LiabilityBridge Note 1-June 18, 2009*Bridge Note II & III-October 26 & 30, 2009Optimus September 24, 2009Other outstanding warrantsTotal Valuation at OriginationChange in fair valueAccreted interest&Total Valuation as of October 31, 20099Bridge Notes IV-December 1, 2009 through January 31. 2010)Bridge Note I- Extension of Maturity Date!Exercise of Common Stock Warrants&Total Valuation as of January 31, 2010 Bridge Note V!Exercise of common stock warrants Note Payoffs$Total Valuation as of April 30, 2010Issuance of Optimus WarrantsBridge Note Conversions#Total Valuation as of July 31, 2010Bridge Note VI Note PayoffIssuance of WarrantsAccreted InterestExercise of Warrants Change in FV#Total Valuation at October 31, 2010&Issuance of November 2010 Bridge Notes&Exchange of November 2010 Bridge Notes%Issuance of January 2011 Bridge Notes#Total Valuation at January 31, 2011 Issuance of Q2 2011 Bridge Notes2Issuance of Long-term Convertible Promissory Notes!Total Valuation at April 30, 2011 Issuance of Q3 2011 Bridge NotesIssuance of May 2011 Notes0Additional warrants issued to Bridge Note holderExchange of Bridge NotesConversion of Bridge NotesConversion of May 2011 Notes,Exchanges/Exercises of October 2007 Warrants Total Valuation at July 31, 2011Issuance of October 2011 Notes/Reclassification of Warrant liability to EquityExchange of Warrants#Total Valuation at October 31, 2011TypeExercise PriceExpirationDateTypeofFinancingCommon Stock Purchase WarrantAugust  October 2012#2007 Securities Purchase Agreement August 2012August 2007 NotesMay 2014#May 2011 Convertible Debt Financing October 2014'October 2011 Convertible Debt Financing $0.15 - $0.17January 2013  April 2015 Bridge Notes August 2014Executive Officer $0.15-$0.1952 February 2012Vendor & OtherMay 2014 - November 2015,Placement Agent  Convertible Debt FinancingSubtotalTBD (1) April 2014-Optimus Preferred Stock Agreement (4/04/2011) Grand TotalSharesWeighted Average Exercise Price4WeightedAverage Remaining ContractualLifeIn YearsAggregate IntrinsicValue"Outstanding as of October 31, 2009Granted ExercisedCancelled or Expired"Outstanding as of October 31, 2010"Outstanding as of October 31, 2011(Vested & Exercisable at October 31, 2011AsummaryofthestatusoftheCompany snonvestedsharesas ofOctober31,2009,andchangesduringtheyearsended October31,2010and2011arepresentedbelow:Numberof Shares-Weighted Average Exercise Priceat GrantDate6WeightedAverage Remaining ContractualTerm (inyears)%Non-vested shares at October 31, 2009Options GrantedOptions Vested%Non-vested shares at October 31, 2010%Non-Vested shares at October 31, 2011(Net operating loss carryforwards-federalStock based compensationValuation on warrantsOthersLess valuation allowa<nceYearended October31, 2011Yearended October31, 2010Pre-Tax Book Income (Loss)34.00% Perm Item-19.61%Change in Valuation Allowance-16.93%2.54%-%Level3 2011!Fair Value of Embedded DerivativeCommon Stock WarrantsOctober31,2011Level1Level2Level3oCommon stock warrant liability, warrants exercisable at $.15 - $0.1952 from February 2011 through November 2015UEmbedded derivative liability, convertible at $0.15 from August 2011 through May 2012October31,2010lCommon stock warrant liability, warrants exercisable at $.15 - $0.287 from February 2011 through August 2015XC Embedded derivative liability, convertible at $0.15 from October 2010 through May 2011.Beginning balance at October 31, 2010 and 2009BIssuance of embedded derivatives associated with convertible notesNote Conversions and Payoffs;Reclassification of embedded derivative liability to equityEnding balance#Exercises and Exchanges of warrants=Reclassification ofcommon stock warrant liability to equityJanuary 26, 2012/s/Thomas MooreName: Thomas MooreTitle: Chief Executive Officer/s/Mark J. RosenblumName: Mark J. RosenblumCTitle: Chief Financial Officer, Senior Vice President and SecretaryDate: January 26, 2012/s/ Thomas MooreName: Thomas MooreTitle:Chief Executive Officer/s/ Mark J. Rosenblum<Chief Financial Officer, Senior Vice President and Secretary* M9k,ncc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} &} ,,,,,,,                ~ C~ /~  O ~   ~ [~ /~  k ~ 3 ~ gQ?~  g ~ G ~ G~ 7~  O ~ +       PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} $} }  } }  } } } }  } }  } }  } }  }  ,@,,,,, , ,                        ~ \      ~ ~ L~ ~ z  ~ \  ~  b= ~ ~  ~ z~ ~ 4  ~ ~    ~ ~ &  ~ BB~  B  ~ o.~ _%  ~ BB~ e ~  .,~ n  ~  ~ ; ~ {        PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } } } }  } } } } } } } } } } } !!!,!,@!,!,!,!,!,!, !, !, !, !, !, $           ! " # $ %           &   '~ + ( ' ) '  '~ | '  'M? * ' ' '  '~ (VaQ  '~ ? + ' ' '  ' ,j   '~ + ( ' ' '  '~  '  '|?5^? - ' ' '  '~ '  '~ k . ' ' ' ' O  ' Q? / ' ' ' '~ - [ '~ ? + ' ' ' ' ~ ( ZX ' JY? 0 ' ' ' '~ j 0 '~ ? + ' ' ' '     PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } } } } } }  } ,@,,,,,  1 2  3  4 5       6~ "N~ <~     '~  7~ Z<   '~  8~ }<   '~  9~ *w   '~ *r   PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} B} }  } } }  ,@,,,,,,, , , : ; <   &|N = 6 > 9mh ? 7n @ 8_G A ,>: B  e A C B8 D"PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,} }  } }  } ,@,,,, E F G~ \~ rT H~ G~ q I~ ~  ~ ] ~ 2PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , ,,,,,,,~  Jffffff$@ K~  L~ C M~ k N~  O~  P~  Q~   R~  S~  T= ףp=$@ UPHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ",,,, , , ,,,,,,,,,,(\B$@ V~  W~  X~  Y~  Z~  [~  \ffffff$@ ]Qk$@ ^q= ףp$@ _~  `~  a~  b~   c~  d~  e!,~ ! !fPH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ",,,, , , ,,,,,,,,,,~  g~  h~ # i~ ' j~ + k~ / l~ 3 m~ 7 n~ ; o~ ? p~ C q~ G r~ K s~ O t~ S u~ W v!,~ ![ !wPH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} &,,,, , , ,,,,,,,,,,~ _ x~ c y~ g z~ k {~ o |~ s }~ w ~~ { ~  ~  ~  ~  ~  ~  ~  ~  !,#,%,~ ! !~ # #~ % %PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,, , , ,,,,,,~  ~  ~  ~  ~  ~  ~  ~  ~  ~  ~  ~  PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} } } ,,,,, , ,,              PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } ',@,,,,,,, , , , ,,,,,,,,,,,,,,,,         ~ jB~ v ~ r)   ~  ~ I~ Y ~ "  ~ b~ . ~ @<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ]} }  } }  }  } }   ,@ , , , , , , , , , , , , , , , , , ,,,,,                ~  ~  q  ~  ~  ` ~ ~-~ Zw~    ~ R~ ~   ~ d~ <~  ʣ  ~ f2~ (~ 9 ~ 5~ ~ Z% ~ n,~ ~ vH ~  ~  ~ S~ "2~  o ~ R~~ Z [~  ^) ~ B)~  ~  v` ~ ~ bl~  B ~ ] ~  ` ~ ~ bl~  f)  ~    Q뱿 ~    Q뱿 ~ %5~ # ~ %5~ #     PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Y} }  } }  }  } } }  } }  } }  } }  } }  } f  , , ,@ ,, , ,, , , , , ,, ,,, , ,, ,,,, , , , , , , ,                            ~ j5~ W      ~ W ~  q~  ~ b   ~  ~   ~ ~  ~ ~ "~  n~  ~ d ~ n~   ~  ~  ~ v   ~ ~  ~    ~ ~    ~ >y~ >y  ~ b~ ~ ~  ~  n~  ~ 2~ H~   ~  ~  ~ RR  ~ (~ (  ~ S~ S ~  ~ RR ~  ~  n~  ~ ~ Ú~ b>  ~  b-~  ~ > ~  b-~  ~ >  ~ r~ r ~  e~ b! ~ :K%~ l% ~  )~  ~ ~   ~  j#~ . ~ $ ~ - ~  ~ b ~ %~ +  ~ ~   ~ ȑ~ ȑ ,! ,",# ,$ ,% ,& ,' ,( ,) ,*,+ ,, ,- ,. ,/ ,0 ,1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,: ,; ,< ,= ,>,? ,  ~ "~ " !~ ! r2~ !L! !~ !><!~ !J,!~ !^j! " # #~ #~ ~ #~ $ $~ $_~ $_ %~ % k~ % %~ %3~ %O &~ & ~ & &~ &U~ &*Y '~ ' B!~ ' '~ '}~ 'j ( (~ (B~ (B )~ ) B ~ )t )~ )i~ )D~ ) * +~ + ~ +r +~ +*8~ +< , ,~ ,w~ ,w - -~ -d~ -d . .~ . ~ . /~ / ꫩ~ /l /~ / <~ /* = 0~ 0 k~ 0 0~ 0z~ 0" 1~ 1 #C~ 12 1~ 1x ~ 1J 2 2~ 2:[~ 2:[ 3 3~ 3.1j~ 3.1j 4~ 4 f;~ 4֖4 4~ 4r4~ 4u4~ 4.4 5~ 5 6 ~ 5R 5~ 5: 5~ 5 6 6~ 6=~ 6= 7 7~ 7j~ 7j 8 8~ 8~ 8 9~ 9 <~ 9 9~ 960~ 9? :~ : c ~ :j :~ :~ :b ;  ;~ ;zd~ ;zd < <~ <zh~ <zh = ~ = U~ == =~ =z;=~ =2=~ == > ? ~ ? ~j~ ?3 ?~ ?r~ ?@ ,A ,B ,C,D ,E ,F ,G ,H ,I,J ,K ,L ,M ,N ,O ,P ,Q ,R ,S ,T ,V ,W ,X ,Y ,Z ,[ ,\ ,] ,^ ,_ , @  @~ @~ @ A  A~ A^%~ A^% B B~ B~ B C D~ D D~ D~ D E~ E ~ E E~ Ev~ E F~ F q~ F( F~ F~ F., G G~ Gr8~ Gr8 H~ H ~ HH H~ HJ.H~ H H~ H¶?H I J~ JV J J~ JĠ~ JĠ K ~ K [~ K~ K bu~ K'r~ KvV L~ L~ L M~ M "ˬ~ M~ M~ M N~ N ~ N6~ N2$~ NP$ O~ O f~ O~ O?~ OE P~ P -~ P ~ P~ P  Q~ Q j~ QF~ Q Q R~ RJq*~ RB S~ Sbl~ Sbl T~ TV T~ T F;/~ TV T~ T buT~ TbT~ TvT~ TxT V~ V V~ V*Tf~ V*Tf W~ Wz W~ W7~ WI@~ W X ~ X z~ X*g~ X(n~ X`~ X~ Y~ Y+~ Y+ Z~ Z~ Z [~ [ D~ [~ [ln~ [vo \~ \ }d~ \F[~ \D]~ \6] ]~ ] ~ ]~ ]\~ ]>" ^~ ^ :-~ ^ ~ ^.~ ^ _~ _ VX~ _6~ _~ _B ` ,a ,b ,c ,d ,e , ` ~ `A~ `A a!~ a"~ a" b"~ ba ~ ba c~ cj~ cj d~ d~ d e#~ e e~ e  b;~ eDe~ ee~ e*e~ ePe~ e~e                 !!!!!!!!!!""##$$%%&&''(())**++,,--..//0011223344444444445566778899::;;<<==========>>??@@AABBCCDDEEFFGGHHHHHHHHHHIIJJTTTTTTTTTTeeeeeeeeeePH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} K} }  } }  }  } } 5  , , , , , , , , , , , , , , , , , , , , , ,, , , , , , , , ,    $     %     &  ' '  (  ) )  )       *     ~ ~ bl~  B  + ,~ j0~ "~  -  ~  .~ .s~ b!~ F /  ~  0~ ~ ~    1~ ^~ ~  ja 2~  "~  ~  ʤ. 3  ~  r 4~ ڻ~ Z~  b 5~ ~ !~  BK$ 6~ . ~  . ~  ~   7~ j,~ o~   8 9~ 6~ ~  ~ :~ ~    ;~ N ~  N <~ j~ r~  F =~ ~ b ~  & >~ B#-~ ~  r ?~ ^~~ 3 ~  < @~ N~ ~   ,! ,",# ,$ ,% ,& ,',( ,) ,* ,+ ,, ,- ,. ,/ ,0 ,1 ,2 ,3 ,4 , A~  ~  !B~ !,~ !w~ ! X "C #D # #~ # A $E $~ $=~ $  %F~ %j~ %.~ %  N &G~ &j~ &~ & ."B 'H (I~ (I:~ (~ ( y )J~ ) )~ )  *K~ *by *~ * NS +L~ +l~ +bL~ + BS ,M~ ,v ~ ,f@~ , [ -N~ -BQ~ -?~ -   .O . .~ . a /P~ /&9B~ /B` ~ / fL 0Q 0 0~ 0  1R~ 1v:p~ 1[~ 1 r 2S~ 2O<~ 2W~ 2 jB 3T~ 3v~ 3E( 3  4U~ 4jB4~ 4v4~ 4 jB4         444444 PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }   ,@ , , )         V~  ~ ~  ") B   PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} b} }  } }  }   , , , , , , , , , , , , , , , , , , ,    $     W  ' '  (  X )  )       Y Z~ 2 [ Z~  \ Z~  ] Z ~   ^ Z ~ *,  _~ = ~  ~ 'd  ` Z ~   a Z ~ E~ E  b~ ~ JS#~  dx  c Z~   d~ }/~ u+~  &a  e~ ~ ~   >b  f Z~ :[ g  Z~ z/                  PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 0} }  } }  } ,,,,,, h    i~ 3 ~ $ j~ R~ qO k~ zs~   ~ >6~ PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Q} }  } ,@,,,, l m~ B n~ r o~ B p~ h{PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,@,,,, q q   r s t u v v w~ ~  x y z2PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,@,,,,,   {~ b'~ b' |~ >~ N.q }~ f ~  ~~ ~  ~ R~ 2PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } ,,,,,,   ~  ~  ~  ~  ~ PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} $} }  } }  }  ,@,,,,,,,   ~ i ~   ~ JN ~   ~ "~ B ~ * ~ ҄~ ҄~ :~ V'2PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} N} }  }  ,,,,,,,, , , , ~  ~ j ~ ^أ ~ .d ~  ~  ~ e ~  ~   ~ 9 ~ 6   PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 9} }  } }  }  } } }  } L,@,,,,,,, , , , , ,,,,,,,,,,,,,,,,,,,        ~ f E~ [ ~  bH ~ ji+ ~  ~ .~  *~ 5   ~      ~  ~`   ~ 2~ ~   ~ i`   ~  L~   ~ p    ~ 2 ~ t ~  ~ PB  ~ !~ ~  ~    ~ \ ~ O   ~ y~ V  ~ ^?     ~    ~ ~  ~   ~ ~h ~ '~ >~  ~     ~  :bG~ r  ~ 2      ~  f  ~ >~   ~ z ~ ~ Z,~  b~ nA   ~  ʃ  ~ El   ~ +   ~  >~ V  ~       ~  J  ~ R~ : ~ ށ8~ ~  I ~ @ ~ 3~ ƍ~  i~ g ~ j   ~ ~"   ~  ?  ,!,",#,$,%,&,',( ,),* ,+,,,.,/,0,1 ,2,3 ,4,5,7,8,9,: ,;,<,=,> ,?,  ~    ! ! !~ ! J ! " " "~ " f~ "2' #~ # o/#~ #V#~ # # ~ ## $~ $8~ $~ $ ~ $2* %~ %^ ~ %^ ~ % N~ % &~ &6~ &V~ & › ~ & '~ ' (~ ( + )~ ) *~ *  +~ + ~ + ,~ ,y~ ,6W~ , ~ , .~ .~ .~ . Zf~ .Z /~ /;& / 0~ 0A~ 0£ 1~ 1 ↶ 2~ 2*u 3~ 3  4~ 4 r,~ 4. 5~ 55~ 5^r5~ 5 :5 ~ 5R@5 7~ 7ַ~ 7~ 7 M~ 7N 8~ 8~ 8^ 8 ~ 8 9~ 9d~ 9u :~ : b8 ;~ ;}~ ;}~ ;) <~ <~ < =~ =~ = >~ > ƍ ?~ ?>@,A,B,C,D,E,F,G ,H ,I,J,K, @~ @ v__~ @C} A~ ANoA~ AP~ A rj~ ARB B~ B~ B  B ~ BJ8 C~ C} D~ DF E~ Ev~ Ez[ F~ F2~ FA G~ G  H~ H 1 I~ I< J~ J r@{~ J K~ K#K~ K]O~ K ~~ K9       ###### ##555555 55AAKKPHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } } } } -}   ,@ , , , , , , , , , , ,        ~ ?~ ,:     ~ ?~ f     ~ ?~      ~ ?~ ZR      ~ V;e     ~ ?~ Bj      ~ G     ~ ? ~ 0    ~ $   ~     ~ 3 j     PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} (} }  } }  }  } } }  }  ,@,,,,,,, , , ,             ~ ^~ C~  ~   ~ ~ C #@~  ~ R~ '~   ~  ~ H_~ 3~  s ~ ˜ ~ qO~ C~   ~ ~c ~ B3~ 3 ffffff"@~       ~ R~ C~  ~ l ~  ?~ C ~  ~  J        PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} } } }  } } 6}   ,@ , , , , , , ,      ~ .~ + ffffff!@ ~ hQ?~  c ~ 9~ +~   ~ F^~ 7 ffffff@ ~ B3~ 3~   ~ 6~ 7 fffff @ ~ ~ ?~  &2PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} (} }  } }  } ,,,,,,,   ~ ~   ~ Y~ _I ~ .:  ~ :  ~ .,x~   "PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } }  }  ,@,,,,,,,              ~ z      2PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !} ,,,,   ~ 9  ~ ~ ~ vҿ"PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } ,, , ,                  Z~ ~~  ~    Z~ 9~  9 r    PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} } } ,, ,,                Z ~ ~      ~   ~ z    PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} B} }  } }  } ,@,,,,,,   ~ ~ PB ~ ~  ~ @~  ~ >`  ~ 3~  " ~ 9~ 2PH00(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} =} }  } }  } ,@,,,,,,   ~ ~  ~ )5~   ~ ^t~ f$ ~ 7  ~ h~ ګ ~ ~~ 2PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } ,,,,    PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} C} ,,,,     !PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } } ,,, " # $ % & ' PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } <} ,,, " ( $  & ) PH0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@ N@ N՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8h